on certain organs.
For this reason, it is impossible to determine if a drug is “bad” solely from its name. The dosage, the indication, the patient’s age, other treatments, and medical history can completely alter the assessment.
Fenfluramine, a particularly closely monitored example
Among the drugs mentioned in the 2022 report is fenfluramine, marketed under the name Fintepla and used in certain severe forms of epilepsy, including Dravet syndrome.